Denis Pasler, Acting Governor of the Sverdlovsk Region, visited Medsintez Plant in Novouralsk

On September 3, 2025, Denis Pasler, Acting Governor of the Sverdlovsk Region, paid a working visit to Medsintez Plant LLC, one of the systemic companies of the Russian Federation. The purpose of the visit was to assess the scale of import substitution in pharmaceutical production, get acquainted with the latest developments of the plant, and discuss prospects for the regional pharmaceutical industry.

During the visit, the head of the region was shown the modern production facilities of the full-cycle enterprise, which include the production of finished dosage forms and active pharmaceutical ingredients using biotechnological, chemical and solid-phase peptide synthesis methods, as well as licensed quality control laboratories. Particular attention was paid to the key projects of the plant, which are part of the state import substitution program being under implementation.

Medsintez Plant is the flagship of domestic pharmaceuticals. The company has been ensuring the drug safety of the country for over 20 years by producing vital drugs that meet international GMP standards. «Today, Medsintez is fulfilling an important state task of introducing import-substituting developments, including hypoglycemic drugs for the treatment of diabetes,» noted Denis Pasler.

The Acting Governor was informed that the company fully meets Russia’s needs for genetically engineered human insulin Rosinsulin and its analogues, as well as covers up to 200% of the need for the first Russian recombinant follicle-stimulating hormone (FSH) Primapur for infertility treatment. More than 35,000 children have been born through IVF programs using this Russian drug.

Furthermore, the plant's management presented their latest achievements, such as the launch in 2023, together with the Promomed Group of Companies, of the first Russian production of hypoglycemic agents Liraglutide and Semaglutide (GLP-1) for the treatment of type 2 diabetes, which helped eliminate the shortage of this group of drugs on the market. Additionally, the company has established the production of Vinsuvet, the first Russian species-specific insulins for veterinary use, separately for cats and dogs, as well as insulin and FSH drugs for small ruminants and cattle.

In 2024, the company established full-cycle production of the world’s first registered recombinant human albumin drug (blood substitute). The drug is identical to natural human albumin, but unlike it, the production process eliminates the risk of contamination of the drug by viruses and associated blood plasma proteins. The production of recombinant albumin does not depend on the number of donors and allows to produce the drug on a large scale.

In addition, the head of the region was presented with plans for 2025 to reconstruct and expand the production facilities for new drugs based on in-house substances, such as human chorionic gonadotropin (hCG), Cetrorelix, used in the IVF procedure, Semaglutide (analogue of Ozempic), Tirzepatide, etc. for the treatment of type 2 diabetes. The project includes design, civil works, installation of clean rooms, purchase and installation of a cartridge filling machine. Upon completion, the project will increase production capacity by 60% to 55 million units per year and expand the portfolio of drugs to meet market demands.

Also, it was highlighted that the plant had played a significant role during the pandemic due to the production of the original Russian antiviral drug Triazavirin, the only drug in Russia approved by the Ministry of Health for both treatment and prevention of COVID-19. Triazavirin is recommended by the Ministry of Health of the Russian Federation for the treatment of influenza and ARVIs in adults. Moreover, in 2022–2023, multicenter clinical trials of the drug at a dosage of 100 mg for the treatment of ARVIs in children aged 12–17 and 6–11 were successfully completed. Triazavirin showed a high efficacy and a good safety and tolerability profile.

«The company not only addresses the current challenges of import substitution but also actively carries out research and development. Plans include mastering the production of new long-acting insulin drugs and other critical drugs, including those based on monoclonal antibodies. I am confident that Medsintez Plant will continue to be the leader in domestic pharmaceuticals and a reliable partner of the state,» emphasized Alexander Petrov, Chairman of the Board of Directors of Medsintez.

Medsintez Plant develops innovative drugs thanks to its own research and high-tech production facilities. The company combines expertise in biotechnologies, close collaboration with research institutes, and the unique ability to independently develop drug administration devices. This integrated approach enables the plant to bring highest-quality drugs to the market and set new standards in the pharmaceutical industry.

Photo: Department of Information Policy of the Sverdlovsk Region